



N DE LOTE:

TEVA CZECH INDUSTRIES S.R.O., Ostravska 29/305, 747 70 OPAVA-KOMAROV, CZECH REPUBLIC

1210112022

PRODUCT SPECIFICATIONS AND

Page 1 of 5

CERTIFICATE OF ANALYSIS

Product Name: ERGOTAMINE TARTRATE

Control No.: 72111001620 Order No.: JU00044001 Client Packing Order: 305646

Customer Name: DCS PHARMA AG

Quantity: 24.000 KG Quality Market: EUR,USA

Manufacturing Site: Opava. Czech Republic Original Analysis Date: September 2020

Last Analysis Date: September 2020

Manufacturing Date: August 2020 Re Test date: August 2025

Packaging and storage: Preserve in tight, light-resistant containers at a temperature from +2 °C to

+8°C.Primary package should be maintained in polyethylene bag with

desiccant.

| TESTS AND METHODS | SPECIFICATIONS | RESULTS* | | | |
|---|--|-----------------|--|--|--|
| SV-721110-01, rev.6 TESTS | | | | | |
| Description Visual | White to almost white crystalline powder. | Complies | | | |
| Identity (IR) EP, (2.2.24), EP monograph | The IR spectrum of the tested substance exhibits maxima at the same wavelengths as that of the reference standard obtained under the same conditions | Complies | | | |
| pH value EP, (2.2.3) | 4.0 to 5.5 | 5.5 | | | |
| Related substances (HPLC) AM-AQC-LC1278 | | | | | |
| Ergostine | NMT 0.40 % | 0.15% | | | |
| 8-hydroxyergotamine | NMT 0.20 % | 0.09% | | | |
| Ergotaminine | NMT 0.20 % | 0.07% | | | |
| Any unspecified impurities | NMT 0.10 % | Less than 0.05% | | | |
| Total impurities | NMT 0.60 % | 0.31% | | | |
| Loss on drying EP, (2.2.32) AM-RD-OT033 | NMT 6.0 % | 1.2% | | | |
| Assay (TITR) EP, (2.2.20) | 98.0 to 101.0 % calculated on dried substance | 100.0% | | | |

TEVA Czech Industries s.r.o.

Ostravska 29/305, 747 70 Opava, Komarov, Czech Republic



PRODUCT SPECIFICATIONS AND

Page 2 of 5

CERTIFICATE OF ANALYSIS

Product Name: ERGOTAMINE TARTRATE

Control No.:

72111001620

Order No.:

JU00044001

Client Packing Order: 305646

Customer Name:

DCS PHARMA AG

Quantity:

24,000 KG Quality Market: EUR, USA

Original Analysis Date:

September 2020

Manufacturing Site: Opava. Czech Republic

Last Analysis Date:

September 2020

Manufacturing Date: August 2020

Re Test date: August 2025

Packaging and storage:

Preserve in tight, light-resistant containers at a temperature from +2 °C to

+8°C.Primary package should be maintained in polyethylene bag with

desiccant.

| TESTS AND METHODS | SPECIFICATIONS | RESULTS* |
|---|---|-----------------|
| | SV-721110-01, rev.6 TESTS | |
| Organic residual solvents EP, (5.4) AM-AQC-GC1025 | | |
| acetone | NMT 5000 ppm | Less than 20ppm |
| toluene | NMT 890 ppm | Less than 20ppm |
| methanol | NMT 3000 ppm | 1240ppm |
| | SV-721110-12, rev.5 TESTS | |
| Description Visual | Colourless crystals or white to yellowish-white, crystalline powder. | Complies |
| AM-AQC-LC026 or AM-AQC-LC1278 | Retention time of the principal peak in the chromatogram of the tested substance corresponds to the retention time of the peak in chromatogram of the reference standard. | Complies |

TEVA Czech Industries s.r.o.



PRODUCT SPECIFICATIONS AND

Page 3 of 5

CERTIFICATE OF ANALYSIS

Product Name: ERGOTAMINE TARTRATE

Control No.:

72111001620

Order No.:

JU00044001

Customer Name:

DCS PHARMA AG

Quantity:

24.000 KG

Quality Market: EUR, USA

Client Packing Order: 305646

Original Analysis Date:

September 2020

Manufacturing Site: Opava. Czech Republic

Last Analysis Date:

September 2020

Manufacturing Date: August 2020

Re Test date: August 2025

Packaging and storage:

Preserve in tight, light-resistant containers at a temperature from +2 °C to

+8°C.Primary package should be maintained in polyethylene bag with

desiccant.

| TESTS AND METHODS | SPECIFICATIONS | RESULTS* | | |
|--|---|-----------------|--|--|
| SV-721110-12, rev.5 TESTS | | | | |
| Related substances (HPLC) AM-QC-LC026 or AM-AQC-LC1278 | | | | |
| Ergostine | NMT 0.40 % | 0.15% | | |
| 8-hydroxyergotamine | NMT 0.30 % | 0.09% | | |
| Ergotaminine | NMT 0.20 % | 0.07% | | |
| Any unspecified impurities | NMT 0.10 % | Less than 0.05% | | |
| Total impurities | NMT 1.0 % | 0.3% | | |
| Specific optical rotation USP, <781S> | -165 to -155° calculated on ergotamine base | -160° | | |
| Loss on drying USP, <731>, AM-RD-OT033 | NMT 5.0 % | 1.5% | | |
| Assay (TITR) USP, Ergotamine tartrate | 97.0 to 100.5 % recalculated on dried substance | 100.4% | | |
| Organic residul solvents USP <476>, AM\AQC\GC1025 | | | | |
| acetone | NMT 5000 ppm | Less than 20ppn | | |
| toluene | NMT 890 ppm | Less than 20ppm | | |
| methanol | NMT 3000 ppm | 1240ppm | | |

TEVA Czech Industries s.r.o.

Ostravska 29/305, 747 70 Opava, Komarov, Czech Republic



PRODUCT SPECIFICATIONS AND

Page 4 of 5

CERTIFICATE OF ANALYSIS

Product Name: ERGOTAMINE TARTRATE

Control No.:

72111001620

Order No.:

JU00044001

Customer Name:

DCS PHARMA AG

Quantity:

KG 24.000

Quality Market: EUR, USA

Original Analysis Date:

Client Packing Order: 305646

September 2020

Manufacturing Site: Opava. Czech Republic

Last Analysis Date:

September 2020

Manufacturing Date: August 2020

Re Test date: August 2025

Packaging and storage:

Preserve in tight, light-resistant containers at a temperature from +2 °C to

+8°C.Primary package should be maintained in polyethylene bag with

desiccant.

| TESTS AND METHODS | SPECIFICATIONS | RESULTS* | | |
|-------------------------------------|----------------|----------|--|--|
| CS01, rev.1 TESTS | | | | |
| Particle size (laser) AM-AQC-OT1012 | | | | |
| D10 | NMT 5 um | 3um | | |
| D50 | NMT 15 um | 10um | | |
| D90 | NMT 40 um | 21um | | |

Remarks:

- 1. Conforms to the requirements of the SV-721110-01, rev.6 and SV-721110-12, rev.5 and CS01, rev.1 Specifications.
- 2. Conforms to the current EP monograph and the In house tests.
- 3. Conforms to the current USP monograph.
- 4. The following residual solvents Class 1, as defined in the ICH Q3C, benzene, carbon tetrachloride, 1,2-Dichloroethane, 1,1-Dichloroethene and 1,1,1- Trichloroethane are not present in the Active Pharmaceutical ingredient.
- 5. The product meets the requirements for residual solvents according to the current USP <467>, PhEur Chapter 5.4 and ICH Q3C
- 6. The product has been produced and controlled in compliance with GMP rules and valid documentation. Tested parameters comply with the approved specification.
- 7. We declare that the batch was produced according to the currently valid R1-CEP 2007-328-Rev 03.

TEVA Czech Industries s.r.o.



PRODUCT SPECIFICATIONS AND

Page 5 of 5

CERTIFICATE OF ANALYSIS

Product Name: ERGOTAMINE TARTRATE

Control No.:

72111001620

24.000

Order No.: Client Packing Order: 305646

JU00044001

Customer Name:

DCS PHARMA AG

KG

Quality Market: EUR, USA

Quantity:

Original Analysis Date:

September 2020

Manufacturing Site: Opava. Czech Republic

Last Analysis Date:

September 2020

Manufacturing Date: August 2020

Re Test date: August 2025

Preserve in tight, light-resistant containers at a temperature from +2 °C to

+8°C.Primary package should be maintained in polyethylene bag with

desiccant.

Quality Control Manager:

Packaging and storage:

Signature**: PP\ Marketa Szebestova

23 September 2020 11:49:08

Bohumir Biba

Print Date: 23 September 2020

Approval: Martina Handlova

(*) Upon completion of the 'Results' column this document becomes a certificate of analysis

End of C.O.A.

(**) This document was signed electronically and this is the manifestation of the electronic signature.

TEVA Czech Industries s.r.o.

